A staging system for patients with renal AL amyloidosis, based on eGFR (<50 ml/min/1.73 m 2 ) and proteinuria (5 g/day) at diagnosis, as well as criteria for renal progression (25% eGFR reduction) and response (30% reduction of proteinuria without renal progression) were recently proposed. We validated these criteria in a cohort of 125 patients with renal AL amyloidosis, mostly treated with bortezomib or lenalidomide. We confirmed the prognostic value of the renal staging system but also identified the limitations of renal progression criteria which are based only on eGFR reduction. We identified the ratio of 24h proteinuria to eGFR as a sensitive marker of renal risk which also accounts for changes in both proteinuria and eGFR: 24h proteinuria/eGFR ratio <30 (in mg/ml/min/1.73 m 2 ) was associated with a 2-year progression to dialysis rate of 0% compared to 9% for a ratio of 31-99 and 35% for a ratio 100 (P < .001). In landmark analysis, patients who achieved a reduction of this ratio by at least 25% or 100 (if initially >100) at 3 months had a 2-year progression to dialysis of 0% vs 24% for patients who either did not reduce to or still had a ratio >100 (P 5 .001); similar results were obtained by applying the same criteria at 6 months; thus, the evaluation of treatment effect on renal function may be identified early.
| I N T R O D U C T I O N
Primary systemic (AL) amyloidosis is a plasma cell disorder characterized by the tissue deposition of monoclonal light chain derived amyloid fibrils that result in progressive multi-organ failure.
1,2 Renal involvement by amyloidosis is one of the most common complications of the disease, usually manifested as nephrotic range proteinuria, 2, 3 and can lead to end-stage renal disease (ESRD) with detrimental effects on the quality of life and survival of the patients. Treatments that reduce toxic light chain load are currently the only therapies that have proven activity and which may delay or stop progression to ESRD. 4 Such treatments target the plasma cell clone and following the reduction of toxic light chain load, improvement of kidney function (as with other organs) may follow. 5, 6 Kidney response is generally characterized by reduction of proteinuria without deterioration of glomerular filtration rate (GFR), 3 but may be delayed several months following hematologic response. 7 However, in several patients kidney function does not improve and eventually ESRD develops despite hematologic response. 6, 8 Thus, it is important to identify those patients who have the highest chance to improve their renal function, start therapy before irreversible kidney damage occurs and identify markers of kidney function that will allow early identification of those who may benefit from an early change in their therapy. In addition, biomarkers associated with renal response may be useful in the evaluation of new therapies targeting amyloid deposits.
In this regard, Palladini et al. formulated a renal staging system that discriminates patients at different risks of progression to ESRD requiring renal dialysis, based on 24-hour urinary protein excretion (more or less than 5 g/day) and estimated glomerular filtration rate (eGFR) (50 or <50 mL/min/1.73 m 2 ). Furthermore, they identified a decrease in 24-hour total urinary protein excretion by 30% (or urinary proteinuria to <0.5 g/24 hours) at 6 months as a marker of early renal response and a decrease of eGFR of 25% as marker of early renal progression. 8 The aim of our study was to validate this system in a different cohort of consecutive, unselected patients with AL amyloidosis, identify improved markers of renal response or progression and also to evaluate the potential effect of different primary therapies in renal outcomes.
| P A T I E NT S A ND M E T H O DS
The current study included consecutive patients with newly diagnosed AL amyloidosis and kidney involvement, which were treated and fol- clinical or laboratory evidence of organ dysfunction, or a biopsy proof of amyloid at an alternate site associated with a 24-hr urine protein excretion >0.5 g/day containing predominantly albumin. 3 Patients with selective Bence Jones proteinuria were excluded from the study. This study was approved by the institutional review board of "Alexandra"
hospital (Scientific Committee of "Alexandra" Hospital). Proteinuria assessed by 24-h urine collection and electrophoresis of the 24 hour protein collection was performed at diagnosis in all patients and thereafter was performed monthly. Serum free light chains were measured by nephelometry using Freelite Serum Free Light Chain Assays (The Binding Site, San Diego, CA). Glomerular filtration rate (GFR) was estimated (eGFR) according to Kidney Disease Outcomes Quality Initiative guidelines using the MDRD formula (eGFR estimated according to serum creatinine). Hematologic response was assessed according to the 2012 ISA criteria. 9 Renal response and renal progression criteria after first line treatment were evaluated on a 3-month and 6 month landmark analysis. 8 
| Statistical analysis
Time to dialysis was calculated from the date of first treatment until the date of initiation of dialysis or of last follow up, if not on dialysis.
Because the prognosis of patients with AL is dominated by the degree of cardiac involvement and because many patients die to cardiac complications before reaching dialysis, our analysis was based on Table 1 .
After a median follow up of 50 months, 54 patients have died, 4-year survival is 57% and estimated median OS exceeds 70 months.
Thirty-three percent (n 5 41) of the patients developed ESRD requiring dialysis, 31% died without requirement for dialysis while 36% of the patients remain alive and have not progressed to dialysis. One-, 2-and 3-year dialysis rates were 19%, 22%, and 30%, while the incidence of death without progression to dialysis was 20%, 29%, and 32% respectively ( Figure 1A ).
| Outcomes according to renal staging
We then evaluated the staging system proposed by Palladini et al. Table 2 . The risk for dialysis was fourfold higher for renal stage 2 vs stage 1 and 7.4-fold higher for renal stage 3 vs stage 1 (P < .001) ( Table 2 and Figure 1B ).
| Renal response and renal outcomes
At 3 months from initiation of therapy, 50% (N 5 54) of evaluable patients (N 5 107) had 30% reduction and 36% (N 5 39) had a 50% reduction of proteinuria. At landmark analysis at 3 months, the relative risk for progression to dialysis was 0.362 (95% CI 0.146-0.897, P 5 .028) for patients with 30% reduction of proteinuria and it was 0.385 (95% CI 0.140-1.059, P 5 .065) for those with 50% reduction in proteinuria. In competing risks landmark analysis, the reduction of proteinuria 30% (vs <30%) at 3 months landmark was associated with a 1-, 2-, and 3-year progression to dialysis of 8% vs 14%, 8% vs 16% and 12% vs 24% (P 5 .09), while death without dialysis rate was 13% vs 16%, 19% vs 32% and 19% vs 38% respec-
At 6 months, 54% of evaluable patients had 30% reduction and 33% had 50% reduction of proteinuria. At landmark analysis at 6 months, the relative risk for progression to dialysis was 0.233 (95% CI 0.083-0.657, P 5 .006) for those with 30% reduction of proteinuria and it was 0.101 (95% CI 0.013-0.762, P 5 .006) for those with 50% reduction in proteinuria. In competing risks analysis at 6 months landmark, the reduction of proteinuria 30% (vs <30%) at 6 months was associated with a 1-, 2-, and 3-year progression to dialysis of 3% vs 13%, 6% vs 17% and 6% vs 30% (P 5 .013), while death without dialysis rate was 6% vs 7%, 18% vs 24% and 18% vs 33% (P 5 .53).
Thus, as proposed by Palladini et al. 13 renal response at 6 months, defined as 30% reduction of proteinuria, is a valid biomarker of better renal outcomes. It is also important that renal responses (i.e 30% reduction of proteinuria) were observed with similar rates across all renal stages (P 5 .866).
| R E N A L P R O G R E S S I O N
At 3 months landmark analysis, eGFR was reduced by 25% in 30% of evaluable patients, and the relative risk of dialysis was 1.635 (95% CI 0.701-3.817, P 5 .256) (Figure 2A ). In competing risks analysis the reduction of eGFR 25% at 3 months landmark was associated with a 1-, 2-, and 3-year progression to dialysis of 9% vs 19%, 13% vs 19%
and 19% vs 24% (P 5 .87), while death without dialysis rate was 9% vs 
| Proteinuria to eGFR ratio as a marker of renal response or progression
Because it is common to see fluctuations in serum creatinine and in the respective calculated eGFR as a result of therapies with diuretics or other drugs and because reductions in GFR also affect the amount of proteinuria, we tried to adjust for this interaction by introducing the ratio of 24h proteinuria to eGFR (UPr/eGFR ratio in mg per ml/min/
m 2
). Baseline ratio of proteinuria to eGFR was associated with the risk of progression to dialysis. In ROC analysis, with initiation of dialysis within 24 months from initiation of therapy as a binary outcome, the area under the curve (AUC) for 24hUPr/eGFR ratio was 0.74 (95% CI 0.62-0.86). Further, we identified a ratio <30 to be associated with a very low risk of progression to dialysis while a ratio >100 was associated with a very high risk of progression to dialysis. A 24hUPr/eGFR ratio between 30 and 99 was associated with an intermediate risk for
dialysis. Thus, a 24hUPr/eGFR ratio <30 was associated with a 1-, 2-, and 3-year progression to dialysis of 0% (no patient progressed to dialysis), for 24hUPr/eGFR ratio 31-99 the 1-, 2-, and 3-year progression to dialysis rate was 7%, 9%, and 11% and for 24hUPr/eGFR ratio 100 it was 30%, 35%, and 46% (P < .001) ( Figure 1C ). The respective death without dialysis rate was 33%, 23% and 15% at 12 months, 41%, 33% & 24% at 2 years and 51%, 36% and 26% at 3 years (P 5 .02).
Importantly, there was a significant correlation of renal stage proposed by Palladini et al. 13 and 24hUPr/eGFR ratio (Supporting Information   Table S2 ). However, by using the three groups per 24hUPr/eGFR ratio, renal stage 2 could be further divided into 3 categories with very different outcomes (Supporting Information Figure S1 ) (P 5 .009).
We then explored the potential of this ratio as a surrogate for renal response at 3 months and at 6 months post initiation of therapy.
At 3 months landmark analysis, patients who achieved a "response" defined as reduction of this ratio by at least 25% or below 100 (if initially >100) had a 2 year progression to dialysis rate of 0% vs 24% for patients who either did not reduce to or still had a ratio >100 (P 5 .001). However, patients with baseline 24hUPr/eGFR ratio >100
at baseline still had an increased risk of dialysis which occurred more than 2 years after starting therapy ( Figure 2C,D) . At 6 months landmark analysis, by applying the same criteria, those patients with a "response" renal responses based on 24h urine protein to eGFR ratios (24hUPr/eGFR). Renal response was defined as reduction of 24hUPr/eGFR ratio by at least 25% and below 100 (if 100) and renal progression was defined as 25% increase from baseline or 24hUPr/eGFR ratio 100 had a 2 year progression to dialysis of 0% vs 22% for "non-responders" (P < .001) ( Table 2 ).
An increase of 24hUPr/eGFR ratio by 25% or to 100 (which was defined as "renal progression") at 3 months was associated with poor renal outcomes with a relative risk for progression to dialysis of 4.233 (95% CI 1.645-10.893, P 5 .003). In competing risks analysis a 24hUPr/eGFR ratio increase by 25% or to 100 was associated with a 1-, 2-, and 3-year progression to dialysis rates of 19%, 22% and 31% vs 2.5%, 2.5% and 6% respectively for those without an increase or with a ratio <100 (P 5 .009). The respective death without dialysis rate was 15% vs 17%, 26% vs 28%, and 30% vs 31% for the 1 st , 2 nd , and 3 rd year respectively (P 5 .9). Thus, quite early in the course of treatment, 24hUPr/eGFR ratio could identify patients at high risk for progression to renal dialysis ( Table 2) .
Hematologic response was associated with renal response as well as longer overall survival. The quality of hematologic response was also associated with lower probability of dialysis: 3-year dialysis rate of patients with hemVGPR or hemCR was 10% vs 22% for hemPR vs 28% for patients with no hematologic response to primary therapy (P 5 .023).
| Primary treatment and renal outcomes
We then evaluated the impact of different types of primary therapy with novel agents (bortezomib or lenalidomide) or other dexamethasone containing regimens (mostly MDex or VAD-like regimens) in renal outcomes. There were no significant differences in the baseline characteristics of patients who were treated with bortezomib-based versus lenalidomide-based regimens or other regimens, including Mayo stage or age (P > .5 for all comparisons) but more patients with eGFR < 50 ml/min/1.73 m 2 were treated with bortezomib than with the other regimens (P 5 .07). In univariate analysis bortezomib-based therapy was associated with a longer time to dialysis than lenalidomide-based therapy: 1-, 2-, and 3-year rate of dialysis was 16% vs 26%, 18% vs 29%, and 23% vs 37% (P 5 .03). There was no difference in the death rates without dialysis for bortezomib-vs lenalidomide-based therapy (P 5 .69) (Supporting Information Figure   S2 ). Rate of dialysis at 1-, 2-, and 3-year was 9%, 16% and 18% for We also evaluated the impact of the different therapies in patients with different renal risk stages. There was no difference in patients with stage 1, which all had excellent outcomes independently of type of therapy. However, among patients with renal stage 2 or 3 bortezomib-based therapy was associated with a 49% reduction in the risk of dialysis (HR: 0.51, 95% CI 0.23-1.1, P 5 .07).
| DISCUSSION
Renal involvement is a common feature of AL amyloidosis and progression to ESRD, requiring dialysis, has a major impact on the life of the patients, treatment should ultimately target improvement of organ function. It is essential to have a staging system that can provide prognostic information on renal outcomes and criteria that can be used to the study from the National Amyloidosis Center by Pinney et al. 6 and also in our study. Further to this staging system, and because there is a relationship between the filtration rate and the degree of proteinuria we identified the ratio of proteinuria to estimated GFR as a marker of renal prognosis. Indeed, this ratio can further discriminate the outcomes of patients with renal stage 2, which includes patients with intermediate risk for progression to dialysis ( Figure 3B ). This is a very simple method based on the two factors that are also used for renal staging, but adding prognostic information without additional testing.
The evaluation of organ response is challenging and previous ISA recommendations regarding renal progression included a 50% increase in the urinary protein excretion (which had to be greater than 1 g/day)
or a 25% worsening of serum creatinine (minimum of 0.5 mg/dL) or creatinine clearance. Palladini et al. proposed eGFR reduction by 25%
at 6 months as a marker of renal progression, associated with a 4.5-fold increase of the risk for progression to ESRD requiring dialysis. Thus, in our cohort, eGFR reduction by at least 25% alone (either at 3 or at 6 months) could not reliably identify those patients at highest risk for progression to dialysis and discriminate from those at lower risk.
The initial difference was only found in the first couple of years and dialysis rate at 3 years was similar for those with and without renal progression. This probably reflects the more advanced degree of renal dysfunction in patients with early reduction in eGFR. We hypothesized that a composite marker which accounts both for eGFR and proteinuria may be more sensitive. Thus, we also evaluated the proteinuria to eGFR ratio as a surrogate for renal response and progression: early on, at 3 months post initiation of therapy, landmark analysis showed that either a ratio >100 or an increase 25% of this ratio was associated with a high risk of progression to dialysis. Our proposal for a 24h proteinuria to eGFR ratio (24hUPr/eGFR) provides a simple and easily available composite marker of renal progression. In addition, this marker seems to be useful early after initiation of therapy i.e at three In agreement with the conclusions of the study by Palladini et al., 13 early recognition and effective therapy of renal amyloidosis provides the best chance of organ function recovery. Unfortunately, for many patients with advanced renal damage (either renal stage 2 or 3, or with a 24h proteinuria to eGFR ratio >100) progression to ESRD is unavoidable even if a deep hematologic response (at least VGPR) is achieved. Importantly, however, achievement of at least a VGPR was associated with better outcome in patients with renal stage 2 and renal stage 3. Thus, a hemVGPR should be the minimum target of therapy of AL amyloidosis.
In our study, we also evaluated the renal outcomes of patients treated with regimens based on bortezomib or lenalidomide, two contemporary regimens for patients with plasma cell dyscrasias. Bortezomib has been considered as the preferable therapy for patients with myeloma and renal impairment 23, 24 but such data have not been available so far for AL amyloidosis. Pending the final results of the prospective study comparing BMDex to MDex in newly diagnosed patients with AL amyloidosis (NCT01078454), our results provide some data regarding the role of these therapies in patients with renal involvement.
We found that for patients with renal stage 2 and 3, bortezomib-based regimens seem to be more beneficial than lenalidomide combinations In conclusion, we evaluated the recently proposed criteria for renal staging in an independent cohort of consecutive patients with renal AL amyloidosis and we confirmed its prognostic value. In addition, we found that the composite marker of proteinuria to eGFR ratio may help to further stratify patients with renal AL amyloidosis and also may be used for the identification of those who are not having adequate renal response. Bortezomib-based therapy seems to offer better renal outcomes than other regimens, but still needs to be prospectively validated.
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